Myriad Genetics, Inc. (MYGN) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024. Myriad Genetics is a leading genetic testing and precision medicine company operating as a single reporting segment. The company focuses on Oncology, Women's Health, and Pharmacogenomics. As of August 2, 2024, there were 90.8 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Testing Revenue | $211.5 million | $183.5 million | $413.7 million | $364.7 million |
| Net Loss | $(36.7) million | $(116.1) million | $(62.7) million | $(170.8) million |
| Net Loss Per Share (Diluted) | $(0.41) | $(1.42) | $(0.69) | $(2.10) |
| Operating Loss | $(36.5) million | $(113.7) million | $(64.4) million | $(165.9) million |
| Cash and Cash Equivalents | $92.4 million (as of June 30, 2024) | |||
| Long-Term Debt | $38.8 million (as of June 30, 2024) | |||
| ABL Facility Availability | $41.5 million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15% year-over-year in Q2 2024, driven by a 9% increase in total testing volumes and higher average revenue per test.
- Prenatal: Revenue up 25% ($44.4M vs $35.6M) due to 12% volume growth.
- Pharmacogenomics: Revenue up 22% ($43.0M vs $35.2M) due to 10% volume growth.
- Hereditary Cancer: Revenue up 19% ($91.5M vs $76.7M) due to 3% volume growth and price increases.
- Tumor Profiling: Revenue down 9% ($32.6M vs $36.0M) due to a 13% volume decrease, largely attributed to the completion of prior-year studies for MyChoice CDx.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased as a percentage of revenue (68.5% in Q2 2024 vs 76.7% in Q2 2023). This improvement was driven by real estate optimization and the absence of the $77.5 million legal settlement charge recorded in Q2 2023.
- Impairment Charges: The company recorded $11.6 million in goodwill and long-lived asset impairment charges in Q2 2024, primarily a $10.2 million charge related to the sale of the EndoPredict business. No such charges were recorded in the prior year.
- Cash Flow: Net cash used in operating activities improved significantly to $16.0 million for the six months ended June 30, 2024, compared to $34.1 million in the prior year period.
Outlook, Risks, and Unusual Items
- Strategic Divestiture: The company signed a definitive agreement to sell its EndoPredict business to Eurobio Scientific for $10.0 million plus contingent consideration. The sale closed on August 1, 2024. Assets and liabilities were classified as "held for sale" as of June 30, 2024.
- Legal Proceedings:
- Stockholder Derivative Actions: A global settlement was reached on April 30, 2024, to resolve consolidated stockholder derivative actions. The company accrued $0.95 million for legal fees. A court hearing was held on August 6, 2024, with a ruling expected shortly.
- Ravgen Settlement: The company has accrued $29.0 million ($5.0M current, $24.0M long-term) related to a settlement with Ravgen, Inc., with payments contingent on litigation outcomes and scheduled installments.
- Liquidity: The company maintains a $115.0 million asset-based revolving credit facility (ABL). As of June 30, 2024, $40.0 million was outstanding with $41.5 million available. The company believes existing resources are sufficient for the next 12 months.
- Risks: Key risks include reimbursement changes, competition, patent challenges, and the ability to achieve profitability. The company notes that inflation impacts labor and supply chain costs.
- Product Launches: Launched the Foresight Universal Plus Test in June 2024. Plans to launch FirstGene, Precise Liquid, and Precise MRD to accelerate growth.
Investor Verification Checklist
- Verify the final closing terms and any adjustments to the $10.0 million sale price of the EndoPredict business.
- Monitor the court ruling on the stockholder derivative settlement to confirm the $0.95 million fee award.
- Track the status of the Ravgen settlement litigation to determine if the contingent $21.25 million payment becomes due.
- Assess the sustainability of the 15% revenue growth rate, specifically the recovery of Tumor Profiling volumes post-study completion.
- Review the impact of the new 12-year lease amendment for the west Salt Lake City facility ($18.2 million future rent) on future cash flows.
- Confirm the company's ability to maintain the minimum liquidity ($60.0 million) and availability ($25.0 million) covenants under the ABL Facility.